Evidence map›Paper›PMID 36474619›Full record

ArticleProstate cancer2022

The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review.

Seyyedmohammadsadeq Mirmoeeni, Amirhossein Azari Jafari, Muffaqam Shah, Fateme Salemi, Seyedeh Zohreh Hashemi, Ali Seifi

Abstract read
In one paragraph

Article in Prostate cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Seyyedmohammadsadeq MirmoeeniSchool of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.ORCID https://orcid.org/0000-0002-5593-3743
Amirhossein Azari JafariSchool of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.ORCID https://orcid.org/0000-0003-3630-5028
Muffaqam ShahDeccan College of Medical Sciences, P.O. Kanchanbagh, DMRL 'X' Road, Santhosh Nagar, Hyderabad 500058, Telangana, India.ORCID https://orcid.org/0000-0003-4219-1960
Fateme SalemiSchool of Medicine, Islamic Azad University of Medical Sciences, Yazd, Iran.ORCID https://orcid.org/0000-0003-4297-7154
Seyedeh Zohreh HashemiResearcher at the Research Center of Tehran University of Medical Sciences, Pharmacology Department, Tehran, Iran.ORCID https://orcid.org/0000-0002-0806-9665
Ali SeifiDepartment of Neurosurgery, Division of Neuro Critical Care, University of Texas Health Science Center at San Antonio School of Medicine, San Antonio, TX, USA.ORCID https://orcid.org/0000-0002-5010-5041

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Prostate cancer (PCa) is the second most common nonskin malignancy and the second most common cause of cancer-related deaths in men. The most common site of metastasis in PCa is the axial skeleton which may lead to back pain or pathological fractures. Hematogenous spread to the brain and involvement of the central nervous system (CNS) are a rare occurrence. However, failed androgen deprivation therapy (ADT) may facilitate such a spread resulting in an advanced metastatic stage of PCa, which carries a poor prognosis. Methods: In this systematic review, we searched the PubMed, Scopus, and Web of Science online databases based on the PRISMA guideline and used all the medical subject headings (MeSH) in terms of the following search line: ("Brain Neoplasms" OR "Central Nervous System Neoplasms") and ("Prostatic Neoplasms" OR "Prostate"). Related studies were identified and reviewed. Results: A total of 59 eligible studies (902 patients) were included in this systematic review. In order to gain a deeper understanding, we extracted and presented the data from included articles based on clinical manifestations, diagnostic methods, therapeutic approaches, and prognostic status of PCa patients having BMs. Conclusion: We have demonstrated the current knowledge regarding the mechanism, clinical manifestations, diagnostic methods, therapeutic approaches, and prognosis of BMs in PCa. These data shed more light on the way to help clinicians and physicians to understand, diagnose, and manage BMs in PCa patients better.

Identifiers

PMID36474619
PMCPMC9719815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.